

Please type a plus sign (+) inside this box +



Attorney Docket P0633D2C2 **PATENT**

CERTIFICATION UNDER 37 CFR 1.10

EM 239524914 US: Express Mail Number

June 23, 1998: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Duene Algemby Vuk

Duane Alexander Vick

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Phillip W. Berman Brian M. Fendly Timothy J. Gregory Florian M. Wurm

Title:

Methods and Compositions for Vaccination Against HIV

- 1. Type of Application
- This application is for an original, non-provisional application. []
- [] This is a non-provisional application claiming priority to provisional application no. _ , filed , the entire disclosure of which is hereby incorporated by reference.
- [] divisional [X] This is a [] continuation-in-part [X] continuation application claiming priority to pending prior application Serial No. 08/802,361 filed on February 19, 1997, which is a continuation of 08/226,162 filed on April 11, 1994 (Patent No. 5,674,984), which is a divisional of 08/101,669 filed on August 2, 1993 (now abandoned), which is a continuation of 07/834,735 filed February 13, 1992 (now abandoned), which is a divisional of 07,504,785 filed April 3, 1990 (now abandoned), the entire disclosure of which is hereby incorporated by reference.
- Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) 2. (Non-provisional)
 - 65 pages of specification
 - pages of claims 3

	page(s) of abstract				
8	sheet(s) of drawings [X] formal [X] informal				
Decla	ration or Oath				
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An executed declaration of the inventor(s) [] is enclosed [] will follow.				
x	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).				
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).				
Assi	gnment				
	(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.				
X	(for cont./div.) The prior application is assigned of record to Genentech, Inc.				
Ame	ndments (for continuation and divisional applications)				
	_ Cancel in this application original claims of the prior application before calculating				
	the filing fee. (At least one original independent claim must be retained for filing purposes.)				
_ <u>X</u>	the filing fee. (At least one original independent claim must be retained for filing purposes.)				
	the filing fee. (At least one original independent claim must be retained for filing purposes.) A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highes:				
	the filing fee. (At least one original independent claim must be retained for filing purposes.) A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119				
Rela	the filing fee. (At least one original independent claim must be retained for filing purposes.) A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119				
Rela	the filing fee. (At least one original independent claim must be retained for filing purposes.) A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119 Amend the specification by inserting before the first line the sentence: is is a non-provisional application				
Rela	the filing fee. (At least one original independent claim must be retained for filing purposes.) A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.) te Back 35 U.S.C. 120 or 35 U.S.C. 119 Amend the specification by inserting before the first line the sentence:				

of co-pending application(s)

X	Serial No. 08/802,361 filed on February 19, 1997, which is a continuation of
	08/226,162 filed on April 11, 1994 (Patent No. 5,674,984), which is a divisional of
	08/101,669 filed on August 2, 1993 (now abandoned), which is a continuation of
	07/834,735 filed February 13, 1992 (now abandoned), which is a divisional of
	07,504,785 filed April 3, 1990 (now abandoned), which applications are incorporated
	herein by reference and to which application(s) priority is claimed under 35 USC §120.
	International Application _ filed on _ which designated the U.S., which application(s)
	is(are) incorporated herein by reference and to which application(s) priority is claimed
	under 35 USC §120 provisional application No filed, the entire disclosure of which is hereby
	incorporated by reference and to which application(s) priority is claimed under 35 USC
	·
	§119

6. Fee Calculation (37 CFR 1.16) The fee has been calculated as follows:

		CLAIN	IS FOR FEE CA	LCULATION	
Number	Filed	Numbe	er Extra	Rate	Basic Fee 37 CFR 1.16(a) \$790.00
Total Claims	25	- 20 =	5	X \$22.00	\$110.00
Independent Claims	12	- 3 =	9	X \$82.00	\$738.00
Multiple dependent claim(s), if any + \$270.00					\$0.00
Filing Fee Calculation					\$1,638.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,638.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9.	Additional Papers Enclosed					
	 Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence. 					
	[] A new Power of Attorney or authorization of agent.					
	[] Other:					
10.	Maintenance of Copendency of Prior Application (for continuation and divisional applications) [This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]					
	A petition, fee and/or response has been filed to extend the term in the pending					
	prior application until A copy of the petition for extension of time in the <i>prior</i> application is attached.					
11.	Correspondence Address:					
_ <u>X</u> _	Address all future communications to:					
	GENENTECH, INC.					
	Attn: Timothy E. Torchia, Ph.D.					
	1 DNA Way South San Francisco, CA 94080-4990					

Respectfully submitted, GENENTECH, INC.

Date: June 23, 1998

Reg. No. 36,700

1 DNA Way

So. San Francisco, CA 94080-4990

(650) 225-8674

Phone: (650) 225-8674 Fax: (650) 952-9881